检验医学与临床2019，Vol.16Issue(4)：464-466,470,4.DOI:10.3969/j.issn.1672-9455.2019.04.009
ADAMTS9-AS2在乳腺癌患者血浆中的表达及其意义
Expression and significance of plasma ADAMTS9-AS2 in patients with breast cancer
宋宏伟 1丛辉1
作者信息
- 1. 南通大学附属医院医学检验科, 江苏南通 226001
- 折叠
摘要
Abstract
Objective To investigate the expression of plasma long chain non-coding RNA (lncRNA) AD-AMTS9antisense RNA 2 (ADAMTS9-AS2) in the patients with breast cancer (BC) and to study its clinical significance.Methods The plasma samples were collected from 44patients with initially diagnosed BC and 48patients with benign breast lesions, while the plasma samples collected from contemporaneous 50age-matched females undergoing the healthy physical examination in the outpatient department served as the control group.The relative expression level of ADAMTS9-AS2was detected by adopting the fluorescence quantitative realtime PCR (qRT-PCR).The statistical analysis was performed on 44cases of BC sample.Then the relationship between the expression level of ADAMTS9-AS2the clinicopathological characteristics of with the age, pathological type, lymph node metastasis, estrogen receptor, progesterone receptor, C-erbB-2, Ki67, etc.was analyzed.Results The relative expression level of plasma ADAMTS9-AS2in 48patients with benign breast lesions was increased except for decrease in two cases.The level of ADAMTS9-AS2was increased in 44cases of initially diagnosed BC, moreover the expression level of ADAMTS9-AS2in BC was significantly higher than that in benign breast lesions, and the difference was statistically significant (P＜0.05).The high expression level of plasma ADAMTS9-AS2was related with Ki67 (P=0.033 8).Conclusion ADAMTS9-AS2is highly expressed in plasma of the patients with BC, which can be used for a potential novel biomarker for early diagnosis of BC.关键词
乳腺癌/长链非编码RNA/ADAMTS9-AS2/生物标志物Key words
breast cancer/long non-coding RNA/ADAMTS9-AS2/biomarker分类
医药卫生引用本文复制引用
宋宏伟,丛辉..ADAMTS9-AS2在乳腺癌患者血浆中的表达及其意义[J].检验医学与临床,2019,16(4):464-466,470,4.
